SCHEMBL4065167

SCHEMBL4065167

CNc1ccc(Oc2ccc(Cl)cc2C)nc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 6/20 0.49
SLC6A4 P31645 6/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2C19 P33261 1/20 0.49
SLC6A3 Q01959 4/20 0.47
GRM8 O00222 1/20 0.44
GRM7 Q14831 1/20 0.44
GRM4 Q14833 1/20 0.44
KCNH2 Q12809 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.42
POLB P06746 1/20 0.40
RAF1 P04049 1/20 0.40
HTR2C P28335 2/20 0.40
HTR2B P41595 2/20 0.40
KDM4E B2RXH2 1/20 0.40
TP53 P04637 1/20 0.40
ALOX15 P16050 1/20 0.40
HTR2A P28223 1/20 0.40
LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8130688 0.82 SLC6A4 (0.53) SLC6A2SLC6A4SLC6A3GRM8GRM7
SCHEMBL4060994 0.82 GRM4 (0.47) SLC6A2SLC6A4CYP1A2CYP3A4CYP2C19
SCHEMBL4061973 0.79 KDM4E (0.60) SLC6A2SLC6A4CYP1A2CYP3A4CYP2C19
SCHEMBL4064115 0.79 GRM8 (0.52) GRM8GRM7GRM4HTR2CHTR2B
SCHEMBL4060811 0.78 GRM8 (0.56) GRM8GRM7GRM4HTR2C
SCHEMBL4058614 0.78 GRM8 (0.53) GRM8GRM7GRM4POLBHTR2C
SCHEMBL4062244 0.77 PNLIP (0.60) CYP2C19GRM8GRM7GRM4POLB
SCHEMBL4061697 0.77 GRM8 (0.55) GRM8GRM7GRM4POLBHTR2C
SCHEMBL4067290 0.77 GRM8 (0.53) GRM8GRM7GRM4L3MBTL1POLB
SCHEMBL4065181 0.76 GRM4 (0.57) GRM8GRM7GRM4TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1028945-B9 SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS AMGEN INC (US) 2009-02-18 EP disclosed
EP-1028945-B1 SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS AMGEN INC (US) 2007-07-11 EP disclosed
US-6458813-B1 2-CYCLOHEXYLOXY-5-(2-CHLOROPHENYLCARBONYLAMINO)PYRIDINE, FOR EXAMPLE; TREATING INFLAMMATION, PAIN, DIABETES, CANCER AMGEN INC. 2002-10-01 US disclosed
US-20020035094-A1 Substituted pyridine compounds and methods of use AMGEN INC. 2002-03-21 US disclosed
US-6333341-B1 TUMOR NECROSIS FACTOR, ANTIINFLAMMATORY AGENTS AND ANALGESICS AMGEN INC. 2001-12-25 US disclosed
US-6184237-B1 Substituted pyridine compounds and methods of use AMGEN INC. 2001-02-06 US disclosed
EP-1028945-A1 SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS Amgen Inc. (US) 2000-08-23 EP disclosed
US-6022884-A PROPHYLAXIS OR TREATMENT OF INFLAMMATION AMGEN INC. (US) 2000-02-08 US disclosed
WO-1999024404-A1 SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS AMGEN INC. (US) 1999-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020035094-A1 Substituted pyridine compounds and methods of use IL1B, IL6, IL1A SLC6A2 3649/4885SLC6A4 3453/4885CYP1A2 222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.